Merck and its partner Ridgeback Biotherapeutics announced on Monday that they’ve submitted an emergency authorization application to the US Food and Drug Administration (FDA) for their oral antiviral Covid treatment molnupiravir.
The US-based pharmaceutical company revealed the request had been made to the FDA, with the hope that it will become the first authorized oral antiviral Covid treatment following positive results from Merck’s Phase 3 clinical trial.
“The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” Merck’s chief executive officer and president, Robert M. Davis, stated in a press release on the company’s website.
Merck described the development as a “critical step” towards making the treatment available to individuals at home, reducing the risk of severe illness and cutting in half the hospitalization rates among individuals infected with the virus.
In the hope that the drug will be given the green light by the FDA, Merck has already begun producing the treatment, expecting to have 10 million courses of molnupiravir ready for distribution by the end of 2021, with more due in 2022.
Anticipating Merck’s successful trials, the US government ordered 1.7 million courses of molnupiravir, as part of a procurement agreement earlier this year, with other supply and advance-purchase deals similarly signed off with countries around the world.
To help boost the production of the treatment, allowing it to be more quickly distributed in low and middle income countries, Merck has agreed a non-exclusive voluntary licensing agreement with Indian manufacturers, hoping to secure authorization to ensure widespread access to the medicine.
If you like this story, share it with a friend!
source: RT
Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.
absolvent WEB DESIGN Academia Britanică de Comunicare Iasi - absolvent COMUNICARE IN AFACERI Academia Britanica de Afaceri si Comunicare -absolvent JURNALISM EDITORIAL - London School University - 2019 inscris la echivalare diploma la Universitatea Politehnica Timisoara - absolvent studii de Drept Universitatea Europeană Drăgan, cursuri in Drept la Universitatea de Vest Timisoara, absolvent studii de proiectare, pastor coordonator in Biserica Protestanta Evanghelica,
Android Developer pe Google Play și plugin developer la Oxwall, creator de teme Wordpress și Oxwall, operator Wordpress, Drupal, Oxwall, Osclass, Moodle, tehnologii HTML și PHP
The former president insisted that the ‘Big Lie’ was the result of 2020 election Donald Trump has swiftly responded to US President Joe Biden’s speech on the anniversary of the January 6 Capitol riot, accusing the Democrat of “destroying our nation” and of playing “political theater” to distract from crises. Trump made abundantly clear in […]
The child’s parent had allegedly been angered over an incorrect order at a McDonald’s drive-through in the US state of Utah A father told his four-year-old child to fire a gun at officers following a dispute over a McDonald’s order, police in Utah have said. The gun was seized from the child just as it […]
Adults in the United States who binge drink are consuming even more alcohol per binging episode, according to a new study published Thursday by the US Centers for Disease Control and Prevention. sursa Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. […]
